Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: A single institutional experience and literature review

Abstract Plasmablastic lymphoma (PBL) is a rare aggressive B-cell lymphoproliferative disorder. HIV-negative PBL has not been extensively reported. Nine HIV-negative PBL patients evaluated at Moffitt Cancer Center were studied. Eight patients had extranodal diseases. All patients were treated with C...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2011-12, Vol.35 (12), p.1571-1577
Main Authors: Liu, Jane Jijun, Zhang, Ling, Ayala, Ernesto, Field, Teresa, Ochoa-Bayona, Jose L, Perez, Lia, Bello, Celeste M, Chervenick, Paul A, Bruno, Salvador, Cultrera, Jennifer L, Baz, Rachid C, Kharfan-Dabaja, Mohamed A, Raychaudhuri, Jyotishankar, Sotomayor, Eduardo M, Sokol, Lubomir
Format: Article
Language:English
Subjects:
Aged
Combined Modality Therapy
Female
Follow-Up Studies
Hematology, Oncology and Palliative Medicine
HIV Infections - epidemiology
HIV-negative patients
Human immunodeficiency virus
Humans
Immunophenotyping
Lymphoma, B-Cell - epidemiology
Lymphoma, B-Cell - therapy
Male
Middle Aged
Plasmablastic lymphoma
Remission Induction
Retrospective Studies
Stem cell transplant
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Plasmablastic lymphoma (PBL) is a rare aggressive B-cell lymphoproliferative disorder. HIV-negative PBL has not been extensively reported. Nine HIV-negative PBL patients evaluated at Moffitt Cancer Center were studied. Eight patients had extranodal diseases. All patients were treated with CHOP or hyper-CVAD. Responses were observed in 8 cases (7 complete, 1 partial responses). Four patients underwent consolidation with autologous hematopoietic stem cell transplant (HSCT) in first complete remission (CR1). At median follow-up of 23.9 months, 7 patients were alive and 5 were disease-free. Aggressive induction chemotherapy and consolidation with autologous HSCT in CR1 might be considered for patients with HIV-negative PBL.
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2011.06.023